|
Prescription Drug Search
Product Request Form
Alemtuzumab is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Alemtuzumab becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Browse Alphabetically:
A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #
Information about ExpressMedsCanada.com
List of countries where we can ship Alemtuzumab:
- Albania
- Algeria
- Antigua and Barbuda
- Australia
- Belarus
- Bolivia
- Bosnia and Herzegovina
- Brazil
- Bulgaria
- Costa Rica
- Czech Republic
- Denmark
- Fiji
- Germany
- Greece
- Guadeloupe
- Guam
- Hong Kong
- Hungary
- Iceland
- India
- Indonesia
- Iran
- Iraq
- Ireland
- Italy
- Jamaica
- Japan
- Korea, South
- Latvia
- Malta
- Philippines
- Romania
- Saudi Arabia
- Serbia
- Slovakia
- Trinidad and Tobago
- United Kingdom, UK
- United States, US
- Uruguay
Latest news releases on Alemtuzumab:
Immunotherapy for Acute Kidney Injury - Medscape News
no antibody induction vs ATG vs IL-2R blockade vs alemtuzumab Significantly higher rate of DGF in ATG group [116] Lymphocyte depletion (alemtuzumab) Retrospective analysis of data from US transplant database comparing outcomes of 14,362 ...
Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec - News-Medical.Net
Starting with the recent launch of fully human, recombinant antibodies binding Rituximab (Rituxan ®) and Trastuzumab (Herceptin ®), AbD Serotec plans to expand this product category with antibodies against Alemtuzumab (Campath ®), Bevacizumab ...
PRESS RELEASE: AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody Therapeutics - ad-hoc-news.de
Starting with the recent launch of fully human, recombinant antibodies binding Rituximab (Rituxan(®)) and Trastuzumab (Herceptin(®)), AbD Serotec plans to expand this product category with antibodies against Alemtuzumab (Campath(®)), Bevacizumab ...
Milestone Triggered in Connection With Filing of New Drug Application in Japan for Arzerra - MENAFN
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(R)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...
Genmab Announces Financial Results for the First Quarter 2012 - msnbc.com
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.
DGAP-Adhoc: Milestone Triggered in Connection with Filing of New Drug Application in Japan for Arz - aktien-meldungen.de
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...
DGAP-News: Genmab Announces Financial Results for the First Quarter 2012 - finanztreff
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...
Genmab A/S : Daratumumab Clinical Data to Be Presented at ASCO and EHA - 4-traders (press release)
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's ...
